PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 30, 2026Signal Transduction and Targeted Therapy0 citationsOpen Access

Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer

XGXiaofan GuoYLYuxiao LiuTLTianchen Li

Key Points

  • This research aims to explore the role of GPR34 in enhancing anti-tumor immunity in pancreatic cancer.
  • Combined GPR34 antagonist with chemotherapy and surufatinib in preclinical models.
  • Assessed anti-tumor immune responses following treatment.
  • Significant enhancement of anti-tumor responses observed in models treated with GPR34 antagonist.
  • GPR34 identified as a promising therapeutic target for improving pancreatic cancer treatment.

Abstract

T cell exhaustion. Combining a GPR34 antagonist with chemotherapy and surufatinib significantly enhanced anti-tumor responses in preclinical models. These findings identify GPR34 as a promising immune therapeutic target.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Guo et al. (2026) studied this question.

synapsesocial.com/papers/69f2f1471e5f7920c638703ehttps://doi.org/10.1038/s41392-026-02641-4
Ask AI
Helpful
Bookmark
Share
View Full Paper